Replimune Q2 FY2024 net loss $60M; cash $496.8M; RP1 data and new CFO announced

Replimune Group, Inc.

2024-Q2 EPS reported -$1.65

Net loss of $60.0M for Q2 ended Sep 30, 2023, compared to $43.1M loss a year ago.
Cash, equivalents & short-term investments $496.8M as of Sep 30, 2023; funds operations into H2 2025.
R&D expenses $49.1M (up from $28.8M) driven by clinical and manufacturing costs for lead programs.
Appointed Emily Hill as CFO; she was previously CFO of PTC Therapeutics.
Topline CERPASS trial data and initial IGNYTE melanoma snapshot expected in early December 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Replimune Group, Inc. reported financial results for fiscal second quarter ended September 30, 2023.

Period: fiscal second quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-115027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.